@ukpdam she actually says 75% but IMO, she should have read 75 of 90 patients so 83% (see captions)
see 5.15 mark - thanks to @randomvirus and @dplane
May be leaked information?
83% would represent IMO, overwhelming efficacy I would have thought !
I’m looking forward to the 90 patient readout by the independent Data Safety Monitoring Board (DSMB) who will complete the first interim analysis of the Phase 3 trial of Remestemcel-L in ventilator dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in early September!
Cell Therapy News/Articles, page-5687
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |